



Program on Opioid Risk Management **Prescription Opioid Abuse: Challenges and Opportunities for Payers**

Colonnade Hotel, June 3 and 4, 2010

Objectives:

- To review and discuss the impact of prescription opioid fraud and abuse on health insurers, other payers, and their customers.
- To develop an understanding of the payers' perspectives on these issues, and clarify the facilitating factors and obstacles in payers' taking proactive approaches to address prescription opioid fraud and abuse.
- To review current knowledge about the effectiveness of approaches to addressing prescription opioid abuse.
- To develop recommendations for payer-based approaches to decrease health consequences and costs associated with prescription opioid abuse.

Time	DAY 1: Thursday, June 3	Speaker
Boston Ballroom, 2nd Floor		
7:30 a.m.	Registration and breakfast	
8:00 a.m.	Introduction	Nathaniel Katz, MD, MS Program Director
8:15 a.m.	Keynote: the complex influence of the prescription opioid abuser on the family of payers	Lisa McElhaney National Association of Drug Diversion Investigators
8:35 a.m.	Discussion	
8:45 a.m.	The costs of prescription opioid abuse to insurers in the US	Howard Birnbaum, PhD Alan White, PhD Analysis Group
9:05 a.m.	Discussion	
9:15 a.m.	Controlled substance fraud: insurance industry perspective	Dennis Jay Coalition Against Insurance Fraud
9:35 a.m.	Discussion	
9:45 a.m.	The impact of insurance reimbursement on the clinical practice of safe opioid prescribing	Michael Brennan, MD Bridgeport Hospital
10:05 a.m.	Discussion	
10:15 a.m.	Prescription opioid fraud and abuse: Medicaid perspective	Gary Gilmore, RPh MassHealth

10:35 a.m.	Discussion	
10:45 a.m.	Break	
11:00 a.m.	Prescription opioid abuse from the private payer perspective	Jeffrey Sterling Wellpoint
11:20 a.m.	Discussion	
11:30 a.m.	Panel of other insurers: auto, property, and workers compensation	Kenneth Jones Travelers Insurance, Special Agent Louis Pagnotta National Insurance Crime Bureau, David Covino Unum Group
11:45 a.m.	Discussion	
Huntington Suite 3, Lobby Level		
12:30 p.m.	Lunch	
Boston Ballroom, 2nd Floor		
Potential Solutions to Prescription Opioid Fraud and Abuse for Health Insurers		
1:30 p.m.	How can payers use prescription monitoring to reduce prescription opioid fraud and abuse?	John Eadie Prescription Drug Monitoring Program Center of Excellence, Brandeis University
1:50 p.m.	Discussant: scientific issues in using PMP data	Nathaniel Katz, MD, MS
2:00 p.m.	Discussion	
2:15 p.m.	Urine drug monitoring: a review of the clinical evidence	Joanna Starrels, MD, MS Albert Einstein College of Medicine and Montefiore Medical Center
2:35 p.m.	Discussion	
2:45 p.m.	The effectiveness of treatment for prescription opioid abuse – a review of the clinical evidence	Roger Weiss, MD McLean Hospital
3:05 p.m.	Discussion	
3:15 p.m.	Break	
3:30 p.m.	The use of SBIRT (Screening, Brief Intervention, and Referral to Therapy) for treating prescription opioid abusers	Bertha Madras, PhD Harvard Medical School
3:50 p.m.	Discussion	
4:00 p.m.	Physician training on safe opioid prescribing: What works?	Rollin Gallagher, MD University of Pennsylvania School of Medicine
4:20 p.m.	Discussion	
4:45 p.m.	Wrap-up of Day 1	Nathaniel Katz, MD, MS
Boardroom, 5th Floor		
5:30 p.m.	Briefing session for Day 2 breakout leaders	Nathaniel Katz, MD, MS George Kenna, PhD, RPh
Huntington Suite 1, Lobby Level		
6:00 – 8:00 p.m.	Poster session/ Wine and cheese reception	

Time	DAY 2: Friday, June 4	Speaker
Boston Ballroom, 2nd floor		
7:30 a.m.	Breakfast	
8:00 a.m.	Opening remarks	Nathaniel Katz, MD, MS
8:15 a.m.	The criminal justice impact of prescription opioid fraud and abuse	Judge Robert Ziemian Dedham District Court
8:35 a.m.	Discussion	
8:45 a.m.	Implementing solutions for health insurers	William Mahon
9:20 a.m.	Break	
9:30 a.m.	Breakouts workgroups:	
Huntington Suite 1 Lobby Level	Group 1: Best practices for health insurers for the prevention and management of prescription opioid fraud and abuse	William Mahon George Kenna, PhD, RPh
Huntington Suite 2 Lobby Level	Group 2: Optimization of clinical care to prevent and treat prescription opioid abuse from the payer perspective	Rollin Gallagher, MD Seddon Savage, MD
Braemore/Kenmore Lobby Level	Group 3: Broad impact on payer community of prescription opioid fraud and abuse	Dennis Jay Lisa McElhaney
Boston Ballroom, 2nd Floor		
11:15 a.m.	Break	
11:30 a.m.	Reports from the breakout groups	
12:30 p.m.	Wrap-up and adjourn	
Kenmore, Lobby Level		
1:00 - 2:00 p.m.	Lunch meeting for authors on breakout group deliverables	Nathaniel Katz, MD, MS